Drug Patents owned by Esperion Theraps Inc

1. List of Nexletol drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7335799 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2025

(2 years from now)

US11613511 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(17 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10941095 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months from now)

US8497301 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months from now)

US10118881 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months from now)

US9624152 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months from now)

US9000041 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months from now)

Do you want to check out NEXLETOL patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 21, 2025

Drugs and Companies using BEMPEDOIC ACID ingredient

NCE-1 date: 2024-02-22

Market Authorisation Date: 21 February, 2020

Treatment: Use of nexletol as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular dise...

Dosage: TABLET;ORAL

More Information on Dosage

NEXLETOL family patents

25

United States

3

Spain

3

European Union

2

Mexico

2

Hungary

2

Japan

1

Canada

1

Cyprus

1

Slovenia

1

Brazil

1

Australia

1

Denmark

1

Portugal

2. List of Nexlizet drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7335799 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2025

(2 years from now)

US11613511 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(17 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000041 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months from now)

US9624152 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months from now)

US10118881 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months from now)

US8497301 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months from now)

US10941095 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months from now)

US10912751 ESPERION THERAPS INC Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
Mar, 2036

(12 years from now)

Do you want to check out NEXLIZET patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 21, 2025
New Product (NP) Feb 26, 2023

Drugs and Companies using BEMPEDOIC ACID; EZETIMIBE ingredient

NCE-1 date: 2024-02-22

Market Authorisation Date: 26 February, 2020

Treatment: Use of nexlizet as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular dise...

Dosage: TABLET;ORAL

More Information on Dosage

NEXLIZET family patents

31

United States

4

Japan

4

European Union

3

Australia

3

Spain

3

Mexico

2

Canada

2

Singapore

2

Russia

2

Brazil

2

China

2

Hungary

1

Korea, Republic of

1

Denmark

1

Chile

1

Cyprus

1

Portugal

1

Ukraine

1

Philippines

1

Morocco

1

Slovenia

1

South Africa

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in